Table 1 Drug anti-SARS-CoV-2 efficacy and cytotoxicity when administered in monotherapy as compared to Cmax obtained from the literature and regulatory documents.

From: The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens

Drug

EC50 (μM)

CC50 (μM)

Cmax (μM)a

COVID-19 clinical trial

EIDD-1931

0.929

>10

11.457

NCT04575597, NCT04405570, NCT04405739, NCT04746183,

BRT

>10

>10

0.140

NCT04421027, NCT04832880, NCT04401579, NCT04891133

EBS

8.448

>10

0.00136

NCT04484025, NCT04483973

SEL

b

4.123

1.218

NCT04349098

MST

4.119

6.705

0.529

NCT04622865, NCT05047783

NFM

>10

>10

0.241

NCT04352400, NCT04390594, NCT04483960, NCT04623021

TPV

b

59.560

5.163

–

SN-38

b

4.784

0.143

–

IMT

6.601

27.250

2.723

NCT04394416, NCT04346147, NCT04422678

RDV

1.267

86.910

3.699

NCT04596839, NCT04292730, NCT04292899, NCT04315948

LPV

b

24.210

19.561

NCT04381936, NCT04315948, NCT04276688, NCT04252885

RTV

b

79.140

20.390

  1. Absolute EC50 and CC50 were obtained from the dose-response curves for each drug individually constructed based on a CPE viral assay with Vero E6 cells. EC curves were plotted after excluding %Inhibition values corresponding to drug concentrations resulting in %Cytotoxicity above 25%.
  2. aDetails on Cmax selection for each drug are specified in Supplementary Note 2.
  3. bEC50 was not achieved within the acceptable cytotoxicity level (below 25%).
  4. Baricitinib (BRT), ebselen (EBS), selinexor (SEL), masitinib (MST), nafamostat mesylate (NFM), telaprevir (VX-950) (TPV), imatinib mesylate (IMT), remdesivir (RDV), lopinavir (LPV), and ritonavir (RTV).
Back to article page